CD34 and plasma cell myeloma: Nevertheless, it is important to note that we and others recently reported that six myeloma patients induced with lenalidomide, carfilzomib and daratumumab, who proceeded to post-induction mobilization and SCT, had a median of 20 × 106 CD34+ cells per kg (range 6.5–38) collected with cytokine mobilization after a median of 4.5 cycles of induction (4–9), and that these 6 patients then underwent SCT with clinical outcomes and hematopoietic recoveries typical for myeloma SCT [17].